Fate Therapeutics (FATE) Tops Q1 EPS by 7c
Tweet
Share
E-mail
Get Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.32), $0.07 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.63 million versus the consensus estimate of $876 thousand.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Starts SSE Plc. (SSE:LN) (SSEZY) at Outperform
- Deutsche Bank Upgrades Dunelm Group PLC (DNLM:LN) to Buy
- Snowflake (SNOW) Tops Q2 EPS by 17c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
